Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients
Status:
Recruiting
Trial end date:
2020-10-31
Target enrollment:
Participant gender:
Summary
The aim of the study was to explore the dose-limiting toxicity (DLT) and the maximum
tolerable dose (MTD) of oral administration of TG02 capsules twice a week for 4 weeks.